This is a one year study whose purpose is to collect information on overall treatment satisfaction in 1000 patients taking Aubagio© (Teriflunomide) for Relapsing Remitting Multiple Sclerosis. This drug has been approved by the FDA in 2012.
- Ages 18 years and older
- May not currently be taking Aubagio© or have taken it in the past
- Women of childbearing potential must be willing to use rigorous birth control